PI3Kδ as a Novel Therapeutic Target in Pathological Angiogenesis
- 8 January 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 69 (4), 736-748
- https://doi.org/10.2337/db19-0713
Abstract
Diabetic retinopathy is the most common microvascular complication of diabetes, and in the advanced diabetic retinopathy appear vitreal fibrovascular membranes that consist of a variety of cells, including vascular endothelial cells (ECs). New therapeutic approaches for this diabetic complication are urgently needed. Here, we report that in cultured human retinal microvascular ECs, high glucose induced expression of p110δ, which was also expressed in ECs of fibrovascular membranes from patients with diabetes. This catalytic subunit of a receptor-regulated PI3K isoform δ is known to be highly enriched in leukocytes. Using genetic and pharmacological approaches, we show that p110δ activity in cultured ECs controls Akt activation, cell proliferation, migration, and tube formation induced by vascular endothelial growth factor, basic fibroblast growth factor, and epidermal growth factor. Using a mouse model of oxygen-induced retinopathy, p110δ inactivation was found to attenuate pathological retinal angiogenesis. p110δ inhibitors have been approved for use in human B-cell malignancies. Our data suggest that antagonizing p110δ constitutes a previously unappreciated therapeutic opportunity for diabetic retinopathy.Keywords
Funding Information
- National Eye Institute (R01-EY-012509)
This publication has 55 references indexed in Scilit:
- Clinical pharmacology of intravitreal anti-VEGF drugsEye, 2018
- Diabetic retinopathy: current understanding, mechanisms, and treatment strategiesJCI Insight, 2017
- Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degenerationBritish Journal of Ophthalmology, 2014
- Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trialThe Lancet, 2013
- PI3K signalling: the path to discovery and understandingNature Reviews Molecular Cell Biology, 2012
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011
- Epidermal growth factor receptor in tumor angiogenesisHematology/Oncology Clinics of North America, 2004
- Epidemiology of diabetic retinopathy and macular oedema: a systematic reviewEye, 2004
- FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibitionTrends in Pharmacological Sciences, 2001
- Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites FluidScience, 1983